Systematic review of patient factors affecting adipose stem cell viability and function: implications for regenerative therapy

1Autologous fat grafting has become a standard treatment for volume and contour defects in reconstructive surgery. In 1983, Illouz and Sterodimas first described fat grafting, where the graft was obtained from a donor site through liposuction and re-injected immediately into the region of interest through syringes. Stem cells isolated from bone marrow (BM-MSCs) are the most characterised and clinically studied stem cell source to date. Passage number, expansion medium, culture conditions and stem cell source all influence mesenchymal stem cell (MSC) characteristics.

2The painful isolation and low yield associated with BM-MSCs has prompted research into other stem cell sources. In 2001, Zuk et al. isolated MSCs from adipose tissue with the same potential as BM-MSCs to differentiate not only into mesenchymal lineages, such as adipogenic, chondrogenic, osteogenic, myogenic and cardiomyogenic lines, but also into neurogenic, angiogenic and hepatic lineages. Adipose-derived stem cells (ADSCs) also display immunosuppressive, anti-inflammatory and angiogenic properties through the release of soluble mediators in a paracrine fashion. This together with the ease of isolation and abundant supply makes ADSCs attractive not only in the regenerative field but also as a tool to enhance the survival of fat grafts. However, fat grafting has two main limitations, inconsistency with fat graft survival and poor reliability.

3Although fat harvesting, processing and injection techniques have been extensively studied and standardised, this has not had a big impact on the variability of outcome following fat grafting. This suggests a possible larger role of patient characteristics on ADSC number, viability and functionality. This systematic review aims to collate evidence on the effect of patient factors on adipocyte and ADSC viability and functionality.

4The isolation procedure for adipose tissue results in a stromal vascular fraction (SVF) layer that is composed of a host of cells, including stem cells, pericytes, monocytes, macrophages and capillary endothelial cells. Dominici et al. provided the criteria to identify MSCs, which include plastic adherence, the expression of CD105, CD73 and CD90, a lack of expression of CD45, CD34, CD14 or CD11b, CD79alpha or CD19 and HLA-DR surface molecules and the ability to differentiate into osteoblasts, adipocytes and chondroblasts in vitro.

5To avoid confusion through terminology, we refer to multipotent precursor cells from adipose tissue stroma as adipose-derived stem cells (ADSCs).

6An electronic search of the MEDLINE through PubMed and EMBASE databases was performed to identity all original clinical papers from 1959 to 2016 that described effects of patient factors, medication or systemic conditions on adipocyte viability, proliferation and differentiation potential (reviewed by two independent reviewers, J.V. and M.G.). For the same time period, all in vitro studies that assessed the effect of patient factors on adipocyte and ADSC function were identified. Keywords with Boolean operators used in the search included the following: “adipocyte” or “stem” or “ADSC” or “lipoaspirate” and “age” or “BMI” or “radiotherapy” or “diabetes” or “menopausal status” or “donor sites” or “HIV” or “cardiovascular disease” or “renal disease” or “gender”. The full search strategy is provided in Additional file 1: Table S1 and Fig 1.

7Articles were considered eligible if they met the following inclusion criteria: (1) clinical, in vitro and animal studies that evaluated the effect of patient factors on adipocyte or ADSC yield and or function; (2) the outcome measures included adipocyte or ADSC or SVF yield and/or function (differentiation and proliferation capacity).

8Articles were excluded if they were: (1) papers describing effects of patient factors on stem cells of other origin, such as BM-MSCs; (2) studies not published in English, as the reviewers could not fully understand the manuscript; (3) editorials, publications on congress meetings, unpublished data or letters to the editor. Review articles were only used to contribute to the “Discussion” section and identify any other relevant articles.

9A variety of names were used in the included studies to describe the plastic-adherent cell population isolated from collagenase digests of adipose tissue. These included adipose-derived stem/stromal cells (ASCs), adipose-derived adult stem (ADAS) cells, adipose-derived stromal cells (ADSCs), adipose stromal cells (ASCs), adipose mesenchymal stem cells (AdMSCs), lipoblasts, pericytes, preadipocytes and processed lipoaspirate (PLA) cells. To avoid confusion we decided to adopt the term “adipose-derived stem cells” (ADSCs) to identify the isolated, plastic-adherent, multipotent cell population as recommended by the International Fat Applied Technology Society.

10Studies were assigned a Level of Evidence (LOE) adapted from the Oxford Centre for Evidence Based Medicine (http://www.cebm.net/index.aspx?o=1025) to establish whether valid and reliable evidence is present for effects of patient factors on adipocyte viability. These levels, ranging from LOE-1 to LOE-5, are based on methodology and study design. In brief, LOEs were assigned as follows: LOE 1 = randomized control trial; LOE-2 = cohort study or cross-sectional study in consecutive participants; LOE-3 = case–control study; LOE-4 = case series study; LOE-5 = animal studies, expert opinion or case report.

11The search for patient factors that affect SVF, adipocyte or ADSC yield and/or function led to the identification of the following factors described in the following sections: age, body mass index (BMI), gender, menopausal status, donor sites, HIV status and cancer treatments, including radiotherapy, chemotherapy and tamoxifen usage.

12Sixteen LOE-2 in vitro studies of human ADSCs and three LOE-5 animal studies reported on the effect of age on ADSC viability and function (Table 1). Twelve of these studies did not identify any effect on adipocyte yield. However, more recent studies using gene expression measurements of senescence have shown a significant decrease in overall yield of nucleated cells with increasing age and, more potently, a significant decrease in the proliferative and differentiation capacities of ADSCs. Madonna et al. compared omental ADSCs between ‘young’ (n = 18, 40–54 years) and ‘elderly’ (n = 22, 66–92 years) and reported significant decreases in ADSC yield and angiogenic capacity with increasing age. While Zhu et al. did not find a significant effect on the adipogenic potential of ADSCs, advancing age significantly reduced osteogenic potential. This is supported by other studies that have reported similar age-dependant decreases in the osteogenic potential of ADSCs. Such age-dependency of differentiation capacity has also been observed in rat ADSCs.

13Fourteen LOE-2 studies investigated the effect of BMI on adipocyte viability. Eight studies demonstrated an effect of increasing BMI on adipocyte viability and function (Table 2). In the largest study to date (n = 189), with 30 women within the ‘obese’ category (BMI >30 kg/m2), van Harmelan et al. reported a significant reduction in the number of viable mature adipocytes per gram of adipose tissue and in the differentiation capacity of ADSCs with increasing BMI. This finding is supported by five other in vitro studies that also showed decreases in both differentiation and proliferation capacities of adipocytes with increasing BMI (Table 2). Frazier et al. reported ADSCs from obese individuals were compromised in early adipogenic and osteogenic potential and correlated this with their potential to form colonies in vitro, which was inversely proportional to the individual’s BMI.

14In addition to the reduced capacity for differentiation and migration and angiogenic and proliferative abilities of ADSCs from obese humans, Perez et al. also noted changes in telomerase activity and DNA telomere length, suggesting a decreased self-renewal capacity and early apoptosis. Isakson et al. and Tang et al. showed that this reduction in differentiation of enlarged ADSCs may be related to increased mitogen-activated protein 4 kinase 4 (MAP4K4) expression, which inhibits peroxisome proliferator–activated receptor (PPAR)-γ activation and thereby adipogenesis.

15It has been reported that after massive weight loss, subcutaneous adipose tissue returns to a non-inflammatory state with a significant decrease in cytokines. Mitterberger compared ADSCs from ‘formerly obese’ patients who had undergone bariatric procedures to ‘obese’ and ‘normal weight’ individuals. They showed that bariatric surgery and diet-induced long-term calorie restriction substantially reprogrammed ADSCs, with reduced DNA damage, improved viability and extended replicative lifespan. ADSCs isolated from ex-obese patients attained a mature adipocyte phenotype faster than those obtained from non-obese patients, suggesting an enrichment of cells in the ADSC population that are ‘more prepared’ for adipogenic differentiation.

16Interestingly, six studies (LOE-2) reported no significant association with increasing BMI. Mojallal et al. reviewed in a prospective study 42 women with varying BMI. After dividing the patients into two groups (BMI ≤25 or >25 kg/m2), they did not find a statistically significant correlation between BMI and proliferation. Similarly, Faustini et al. analysed data from 125 subjects stratified by gender and did not see an association among increasing donor BMI and ADSC yield or function (Table 2).

17Ogawa et al. showed in a LOE-5 study that PPAR-[gamma]2 expression levels (marker of adipogenesis) were 2.89 times greater in ADSCs harvested from female mice compared to male mice, raising the possibility of a significant role of gender. In vitro LOE-2 studies of human ADSCs, however, have so far not shown any difference in ADSC yield and proliferation by gender. Faustini et al. studied 37 males and 88 females and reported that the best donor site among men in terms of yield was the abdomen. Aksu et al. studied abdominoplasty tissue from three males and three females and reported that ADSCs from males showed more effective osteogenic differentiation compared to those from females.

18Three LOE-2 in vitro and one LOE-5 in vivo study in mice investigated the effect of menopausal status or oestrogen on adipocyte viability. Geissler et al. reported increased adipocyte viability using lower abdominal fat from younger, presumably pre-menopausal women (<45 years) compared to from older women, suggesting a modulatory role of circulating oestrogen levels. However, information regarding hormonal status or supplements was not gathered.

19To further examine the effect of circulating oestrogens on fat graft outcomes, the same group later harvested adipose tissue from inguinal pads of mice that underwent either ‘sham’ or ‘ovariectomy’ operations, which was then injected into another set of mice. The fat grafts from mice that had the ‘sham’ procedure, and therefore circulating oestrogen, were softer and showed higher capillary density and higher expression of proangiogenic factors.

20Interestingly, transfer of lipoaspirate into ‘sham’ or ‘ovariectomy’ recipients did not alter the weight or vascular density 45 days after transplantation, suggesting a smaller role of circulating oestrogen post-fat transfer. Addition of 17β-oestradiol to ADSCs has been shown to significantly improve adipogenic differentiation with enhanced survival of fat transfer by reducing apoptosis in nude mice.

21The search for the ideal donor site for fat harvest is ongoing. So far ten LOE-2 in vitro studies using human ADSCs and one LOE-5 animal study have investigated donor site as a potential influence on adipocyte behaviour. Of the ten studies of human ADSCs, only three found any difference in adipocyte behaviour between different sites (Table 3). Padoin et al. (n = 25) showed that fat from the lower abdomen and medial thighs has higher ADSC yield compared to the upper abdomen, trochanteric region, knees and flanks. Jurgens et al. (n = 22) also reported significantly higher ADSC yield from abdominal aspirate with no significant differences in differentiation capacity. Geissler et al. (n = 24) reported greater adipocyte viability in lipoaspirates from lower abdomen compared to from flanks and inner thighs, evident only in a subset of younger women (<45 years). There is some evidence to suggest higher ADSC yields from abdominal tissue compared to back and knee among men. However, this difference was not seen among women. This is in agreement with previous studies suggesting that the choice of donor site has little effect on fat graft outcomes. Within the abdomen, fat superficial to the Scarpas layer displays increased multipotency and stemness features compared to a deep abdominal depot.

22A LOE-5 study by Poglio et al. investigated mice after whole body radiation and reported that adipose tissue can be deeply damaged by radiotherapy, significantly reducing both the number and proliferation capacity of ADSCs.

23Administration of immunosuppressive medications such as anti-lymphocyte treatment and alemtuzumab (lytic monoclonal antibodies) and tacrolimus for lymphocyte depletion following composite tissue transplantation have been shown to decrease both the viability and proliferative capacity of ADSCs in a dose-dependant manner.

24In vitro exposure of human ADSCs to increasing doses of tamoxifen, a selective oestrogen receptor modulator used in breast cancer treatment, resulted in apoptosis, inhibition of proliferation and differentiation in a dose- and time-dependent manner. Interestingly, Liang et al. reported no difference in differentiation potential of ADSCs in vitro when exposed to three commonly used chemotherapeutic agents: cisplatin, comptothecin and vincristine.

25A LOE-2 study compared gene expression profiles of ADSCs in diabetic patients to those in age- and BMI-matched controls. They reported a significant decrease in ADSC differentiation capacity and up-regulation of genes involved in inflammation and apoptosis in the diabetic patients. Harris et al. reported a trend of lower yields of ADSCs in diabetics (n = 18) which was not statistically significant.

26Three LOE-5 animal studies investigated the effect of fat grafting in a diabetic setting. Choi et al. demonstrated a higher resorption in rats with diabetes over 90 days. This was supported by Jung et al. with reports of significantly lower weights, volumes and vascularity in the diabetic group compared to the control group. Ferrer-Lorente et al. used a different approach and analysed gene expression in subcutaneous adipose tissue from Zucker diabetic fatty rats and their non-diabetic controls. The subcutaneous adipose tissue of diabetic rats displayed widespread downregulation of markers of stemness and differentiation and angiogenic potential.

27This review aims to identify patient characteristics that may influence adipocyte and ADSC viability and behaviour in order to have a greater understanding of how to improve fat graft retention rates. Peer first postulated the ‘Cell Survival’ theory, suggesting the number of viable cells within the graft correlated with the long-term survival of grafts. The restorative and reconstructive qualities of fat grafting have been attributed to ADSCs within the graft. Moreover, addition of ADSCs to transplanted fat was reported to support the formation of new vasculature and promote graft retention.

28A total of 41 papers were included in this review. Most were in vitro studies on human tissue (LOE-2) and used similar in vitro techniques to analyse the effects of different patient factors on adipocyte and ADSC count as well as function. However, it is difficult to make conclusive recommendations as it is not clear whether the in vitro findings translate to clinically significant differences. Methods of adipocyte isolation and processing protocols also varied among the studies and this is known to affect yield. The included studies mostly had modest sample sizes and consisted of healthy patients undergoing elective plastic surgery procedures; therefore, the homogeneity in the sample may have reduced the power. Most studies did not report on other ADSC functions such as immunodulatory or angiogenic properties.

29With an aging population, fat transfer procedures, particularly for regenerative properties, are becoming more relevant. Age-related changes in fat tissue inflammatory profiles resemble those in obesity, in which senescent stem cells and endothelial cells accumulate along with an increase in circulating pro-inflammatory cytokines, including TNFα and IL-6. This increased cytokine release by ADSCs activates adjacent cells into a pro-inflammatory state, impeding adipogenesis and promoting fat cell lipolysis.

30Advanced age is known to have detrimental effects on blood and BM-MSCs. In contrast, ADSC yield seemed to be stable across age groups in 12 of 16 LOE-2 studies included in this review (Table 1). The subjects in most of these studies were having elective cosmetic procedures and therefore the homogeneity of subjects, with very few subjects being elderly (>70 years), may have reduced the power to detect an effect. However, it is reassuring to know that ADSC yield appears relatively stable across age groups. Similarly, BMI was also found to have little effect on ADSC yield in 12 LOE-2 studies. Although the absolute yield of precursor cells per gram of adipose tissue was reduced in some studies, this can be explained by the initial increase in adipocyte size seen with weight gain. These findings demonstrate the reproducibility of adipose tissue as a consistent and abundant source of ADSCs across a spectrum of ages and BMI values.

31Unsurprisingly there is evidence to support reduced proliferative and differentiation capacities with increasing age, which is likely related to the decreased susceptibility of precursor cells to respond to extracellular signals. Similarly, increasing BMI, particularly within the obese category (BMI >30 kg/m2), was observed to negatively impact ADSC functional capacities, with implications for their use in cellular therapies and reconstructive surgery (Table 2). Although larger in size, these adipocytes in obese individuals have been shown to be deficient in perilipin phosphoproteins, which are found on the cell surface and act as gatekeepers preventing lipases from hydrolyzing triacylglycerol. This deficiency may contribute to fragile cell membranes, thereby potentially increasing the basal rate of lipolysis. Another important consequence of adipocyte enlargement is the development of local inflammation with infiltration of monocytes/macrophages that act as scavengers of the remaining debris and lipids and higher expression of pro-inflammatory proteins, including TNF-α, IL-6 and factor VII, affecting adipocyte survival and functional capacities in recipient sites. So far no clinical studies have investigated if these cellular changes translate into clinical differences. Graft enrichment through supplementation of ADSCs may be relevant for this cohort, along with weight reduction interventions.

32No clinical studies have yet set out to address associations between gender, menopausal status and hormone replacement therapies and ADSC yield. Circulating oestrogen is a major regulator of adipose tissue, exerting its effects primarily through two oestrogen receptors (ERs), ER-α and ER-β. Studies have shown variable distribution of these receptors among fat depots, affecting responses to oestrogen signalling. Depletion of oestrogen levels, for instance in post-menopausal women or in ovariectomised mice, have been associated with an increase in lipolytic activity, adipocyte diameter, oxidative stress and inflammation.

33In a questionnaire study among 508 surgeons practising in the US, the most preferred site for fat harvest was the abdomen (89%), followed by thighs (34%). So far, clinical studies have not yet been able to identify an ideal donor site. Therefore, when used as fillers, site choice may be made on ease, safety of access, fat abundance and patient preference. Nevertheless, application of grafts harvested from a single depot has been advised, especially for treatment of mirror zones (e.g. nasolabial folds, cheeks ) as there is in vitro evidence that adipocytes from different anatomical depots exhibit different morphology and functional capacity. For example, the distributions of adrenergic receptor subtypes on adipocytes vary between depots, with abdominal subcutaneous depots showing higher concentrations of adrenergic receptors than gluteo-femoral adipose tissue. Therefore, abdominal depots in general are characterized by a higher lipid turnover and undergo increased lipolysis in response to adrenergic stress stimuli.

34In comparison, lower-body fat stores have reduced lipid turnover, retain the capacity to recruit additional adipocytes as a result of weight gain, demonstrate fewer signs of inflammatory insult and tend to be more resistant to TNFα-induced apoptosis than abdominal ADSCs in in vitro studies. New data suggest that these profound functional differences between upper-body and lower-body tissues are controlled by site-specific expression of developmental genes that direct both the degree of adipocyte proliferation and aspects of differentiation. It is accepted, therefore, that adipocytes from different subcutaneous depots (abdominal versus gluteal) are developmentally distinct and are cell autonomous, which means that even after transplantation during fat transfer procedures, they can be expected to have distinct phenotypes. How they interact with the microenvironment in recipient sites has not yet been studied in detail. It is possible gene regulation determines depot-specific properties during development and sex steroids play a modulatory role.

35Additional data are required to determine whether these findings translate into long-term retention. Most studies have rarely considered interactions between gender, BMI, menopausal status and other potential confounders and were of modest sample sizes (Table 3). Nevertheless, current clinical data suggest there is no significant difference in the volume or weight of grafted fat from different donor sites.

36Radiotherapy is increasingly being used to treat numerous human malignancies. Altered molecular signalling and formation of reactive oxygen species cause single-stranded DNA breaks that do not repair completely and activate premature senescence or accelerated terminal differentiation. Despite improved resilience of ADSCs through their superior DNA damage repair mechanisms and reduced metabolic demands that protect them from hypoxia and subsequent apoptosis, studies have demonstrated that radiotherapy adversely affects ADSCs, necessitating the introduction of non-irradiated progenitor cells from distant donor sites.

37Fat transfer in radiotherapy patients is further complicated by the fact that irradiated recipient sites have unfavourable microenvironments for graft survival because of hypoxia and chronic inflammatory states. Furthermore, stem cells within the injured area recruit myofibroblast-like cells, which in turn contribute to fibrosis. The immunoregulatory capacity of transferred ADSCs to modulate inflammation and thereby reduce fibrosis and its normalising role in tissue regeneration have been well documented.

38Use of tamoxifen is routinely discontinued before and after major surgery because of the increased risk of venous thrombo-embolism with no documented effect on increased cancer risk. Given that tamoxifen has a dose- and time-dependant detrimental effect on ADSCs, discontinuing its use to support fat engraftment and survival may be beneficial.

39The link between chronic diseases like diabetes and impaired BM-MSC properties is well established. Evidence collated from LOE-5 animal studies also supports the detrimental effects of diabetes on ADSC function, potentially limiting its potency in regenerative and reconstructive surgery. The effect of other common diseases and medications should also be further investigated. Evidence so far suggests no significant impact of total cholesterol, hypertension, renal disease, physical exercise and peripheral vascular disease on ADSC yield.

40Currently, surgeons aim to improve fat graft resorption by optimising the fat harvest and injection techniques and preparation of the recipient bed. An improved understanding of patient factors that affect fat viability and function would assist in the identification of patient groups that could potentially benefit from graft enrichment techniques. Surgeons may consider transferring larger volumes of processed fat and adopt techniques to boost levels of ADSCs in grafts using techniques such as cell assisted lipotransfer, where part of the lipoaspirate is used to extract ADSCs, which are then used to supplement the cellular suspension before transplant.

41Alternative strategies such as banking younger adipose tissue when biological activity is at its greatest potential or before chemoradiotherapy has become an option with cryopreservation techniques. Transfer of smaller fat particles and serial transfers of smaller volumes at closer intervals may also support adipocyte survival within adverse microenvironments by reducing demand. The search for the ideal fat particle size for transfer is ongoing.

42Overall the literature is sparse, with varied methodologies used to compare the effects of different factors on adipocyte and ADSC functionality. A more uniform comparison of all factors highlighted in this review, with the application of a combination of tests for each outcome measure, is essential to fully understand factors that affect adipocyte and ADSC viability as well as function. This would be crucial information for surgeons when deciding appropriate volumes of lipoaspirate to inject, improve patient selection, and counsel patient expectations with regards to outcomes and likelihood for repeat procedures.